Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

HYPERION THERAPEUTICS, INC.

Home Clinical Trial Sponsors and OrganizationsHYPERION THERAPEUTICS, INC.

HYPERION THERAPEUTICS, INC.

ACTIVE

2000 Sierra Point Pkwy Ste 400, 加利福尼亚州圣马特奥县, California, United Stateswww.hyperiontx.comSubsidiary501–1,000 employeesEstablished: 2006-01-01

Part of Horizon Therapeutics Plc

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

4 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2006

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

Active, not recruiting

4

100.0%

Clinical Trials

Trials sponsored by this organization (4)

A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN 100 Compared to Sodium Phenylbutyrate in Children 6–17 Years of Age with Urea Cycle Disorders, with a Long-Term Safety Extensio

Active, not recruiting

Feb 201517 participants

A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment with HPN-100, in Pediatric Subjects under 6 Years of Age with Urea Cycle Disorders (UCDs)

Active, not recruiting

Feb 201515 participants

A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN 100 Compared to Sodium Phenylbutyrate in Children 6–17 Years of Age with Urea Cycle Disorders, with a Long-Term Safety Extensio

Active, not recruiting

Feb 201511 participants

A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment with HPN-100, in Pediatric Subjects under 6 Years of Age with Urea Cycle Disorders (UCDs)

Active, not recruiting

Feb 201523 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations